Preliminary data are expected this year for a Phase 1/2 clinical trial testing the investigational therapy SRP-1003 in DM1.

Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investors welcomed the company’s receipt of $100 million in ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Some experts worry that patient groups’ growing influence is leading to the approval of drugs that may not work and could ...

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

'Mad Money' host Jim Cramer weighs in on stocks including: Sarepta Therapeutics, Webull, Bitmine Immersion, TE Connectivity, ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

Trump loyalist Laura Loomer is openly campaigning to blunt Health and Human Services Secretary Robert F. Kennedy Jr.’s ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

A well-connected drug company and Laura Loomer wanted Kennedy ally Vinay Prasad gone. Trump chief of staff Susie Wiles got ...